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Abstract: Hepatocellular carcinoma (HCC) biomarkers are lacking in clinical practice. We therefore
explored the pattern and composition of urinary volatile organic compounds (VOCs) in HCC patients.
This was done in order to assess the feasibility of a potential non-invasive test for HCC, and to
enhance our understanding of the disease. This pilot study recruited 58 participants, of whom 20
were HCC cases and 38 were non-HCC cases. The non-HCC cases included healthy individuals
and patients with various stages of non-alcoholic fatty liver disease (NAFLD), including those with
and without fibrosis. Urine was analysed using gas chromatography–ion mobility spectrometry
(GC–IMS) and gas chromatography–time-of-flight mass spectrometry (GC–TOF-MS). GC–IMS was
able to separate HCC from fibrotic cases with an area under the curve (AUC) of 0.97 (0.91–1.00),
and from non-fibrotic cases with an AUC of 0.62 (0.48–0.76). For GC-TOF-MS, a subset of samples
was analysed in which seven chemicals were identified and tentatively linked with HCC. These
include 4-methyl-2,4-bis(p-hydroxyphenyl)pent-1-ene (2TMS derivative), 2-butanone, 2-hexanone,
benzene, 1-ethyl-2-methyl-, 3-butene-1,2-diol, 1-(2-furanyl)-, bicyclo(4.1.0)heptane, 3,7,7-trimethyl-,
[1S-(1a,3β,6a)]-, and sulpiride. Urinary VOC analysis using both GC–IMS and GC-TOF-MS proved
to be a feasible method of identifying HCC cases, and was also able to enhance our understanding of
HCC pathogenesis.
Keywords: urinary biomarkers; hepatocellular carcinoma; diagnosis; volatile organic compounds;
headspace analysis
1. Introduction
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related
death worldwide [1]. In most cases, HCC is considered a consequence of liver fibro-
sis/cirrhosis, with chronic viral hepatitis, alcoholic liver disease, and non-alcoholic fatty
liver disease (NAFLD) being the most common underlying causes [2]. Early detection
of HCC is usually reliant on ultrasound scan (USS) surveillance of cirrhotic patients. In
these patients, the USS detection of HCC lesions varies according to the experience of the
USS operator. Detection sensitivity can range from 40% to 80%. Another test that can
be used for cirrhotic patients is the serum marker alpha-fetoprotein (AFP). AFP has poor
sensitivity and relies on the cut-off being applied. Due to this, the clinical guidelines in
2018 recommended that AFP should no longer be used in routine clinical practice [3,4].
HCC diagnosis relies on advanced contrast-enhanced scans, which are either com-
puted tomography (CT) or magnetic resonance (MR). HCC tissue biopsy is reserved for the
confirmation of inconclusive HCC lesions found on a scan, or for determining the choice
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of palliative chemotherapy in case there is need to differentiate between HCC and other
hepatobiliary malignancies [3–5]. HCC is often diagnosed late due to inaccessibility to CT
and/or MR scans, especially in low-resource settings. Another factor involved in delayed
diagnosis is the absence of symptoms until late in the disease. In addition, HCC has no
approved screening programme for the general population—unlike colorectal, breast, or
cervical cancers [1–5].
Given these factors there is still a need for ways to diagnose and understand the
pathogenesis of HCC. One of the described mechanisms in HCC pathogenesis involves the
impairment of hepatic metabolic pathways. The literature suggests that HCC development
could be related to the malfunction of the cytochrome polysubstrate 450 (CYP450). These
are heme-containing monooxygenases located in the endoplasmic reticula of the hepatic
cells. The main function of cytochromes is to detoxify chemicals that could be harmful
to tissues. However, this detoxification may produce harmful metabolites that could
disrupt the hepatic cellular DNA division mechanisms required to maintain hepatic cellular
proliferation, with subsequent cancer formation [6–11]. Because HCC is a vascularized
tumour, we hypothesized that the byproducts of CYP450, including different volatile
organic compounds (VOCs), would be found in the urine following the homeostatic HCC
cells’ secretion of these compounds into systemic circulation, and subsequent kidney
filtration. We therefore designed a pilot study with the aim of assessing this hypothesis.
2. Results
Figure 1a,b shows the outputs from GC-IMS and GC-TOF-MS, respectively. For the
GC–IMS output, the background is defined in blue, with the red peaks showing areas of
high intensity. The long red line is the output of the instrument to the carrier gas (in this
case, nitrogen). The results show that we were able to separate different chemicals within
the urine sample without saturating the machine and without chemical overlap. For the
GC-TOF-MS output, we see a broad range of chemical peaks throughout the spectra, with
good separation. On average, the total number of peaks detected using GC-TOF-MS, after
analysing HCC and fibrosis samples, was 112, and the total number of peaks detected
among HCC and non-fibrosis samples was 74. Similarly, for fibrosis and non-fibrosis
samples, 79 peaks were detected on average.
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2.1. Results from GC-IMS
Table 1 shows the results of the separation of those with HCC from non-HCC patients
with liver fibrosis. The area under the curve (AUC), sensitivity, and specificity were 0.97,
0.43, and 0.95, respectively. Conversely, the separation of those with HCC compared to non-
HCC patients without liver fibrosis shows modest separation, with an AUC, sensitivity, and
specificity of 0.62, 0.60, and 0.74, respectively. Comparison of both fibrosis and non-fibrosis
patients revealed an AUC, sensitivity, and specificity of 0.63, 0.29, and 0.90, respectively.
The receiver operating characteristic (ROC) curves for the different liver groups, using
GC-IMS, are presented in Figure 2. The optimal threshold values were applied for the
comparison of HCC and fibrosis samples, HCC and non-fibrosis samples, and fibrosis and
non-fibrosis samples, and were 0.39, 0.35, and 0.52, respectively.
Table 1. Statistical results from the GC–IMS analysis (95% confidence intervals are in brackets). Positive predictive value
(PPV); negative predictive value (NPV).
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The results showed that the diagnostic tests gave four false positives for comparison
between HCC and fibrosis samples, eight false positive tests for HCC and non-fibrosis
samples, and only three false positive tests for fibrosis and non-fibrosis samples. Moreover,
the number of false negative tests for HCC and fibrosis samples was only 1, whereas the
number of false negative tests for HCC and non-fibrosis samples, and for fibrosis and
non-fibrosis samples, was 12 and 5, respectively.
2.2. Results from GC-TOF-MS Chemical Identification
Test accuracy for HCC and non-HCC cases using GC–TOF-MS is provided in Supple-
mentary Materials Table S2 and Figure S1. This includes ROC curves for the different liver
disease groups. From the total list of more than 200 chemicals identified using the National
Institute of Standards and Technology (NIST) software, 5 were found to be statistically
significant between the groups, with p-values of <0.05. Further analysis was undertaken
comparing HCC with fibrosis and with non-fibrosis, and an additional two chemicals
were identified from HCC versus fibrosis in the same way. No additional chemicals were
identified when comparing HCC with non-fibrosis. These chemicals are listed in Table 2,
with numbers 1–5 for HCC vs. non-HCC, and the remaining two associated with HCC
vs. fibrosis. This table also includes the chemical retention time, the p-value between the
groups, and whether the abundance of a chemical increased or decreased with HCC. We
have not attempted to quantify these changes here due to the small sample size.
Table 2. List of the relevant chemicals identified using GC-TOF-MS for HCC vs. non-HCC.
No. RetentionTime (min) Chemical p-value
Abundance
Change
1 15.25 4-Methyl-2,4-bis(p-hydroxyphenyl)pent-1-ene, 2TMS derivative <0.01 Lower for HCC
2 2.5998 2-Butanone 0.03637 Higher for HCC
3 4.5684 2-Hexanone 0.04309 Lower for HCC
4 6.3215 Benzene, 1-ethyl-2-methyl- 0.04183 Lower for HCC
5 12.1318 3-Butene-1,2-diol, 1-(2-furanyl)- 0.03247 Lower for HCC
6 8.2054 Bicyclo[4.1.0]heptane, 3,7,7-trimethyl-, [1S-(1a,3ß,6a)]- 0.03553 Lower for HCC
7 13.861 Sulpiride 0.04369 Lower for HCC
In addition, fibrosis and non-fibrosis samples were analysed in the same way. Table S3
in the Supplementary Materials provides a list of the relevant chemicals found in this
analysis.
3. Discussion
In this study we investigated the use of VOCs as a means of providing biomarkers for
the diagnosis of HCC. Here, VOCs were analysed using GC-IMS and GC-TOF-MS, which
we have previously used in other clinical studies [12–14]. Importantly, this study further
consolidates existing published studies utilizing urinary VOCs for cancer detection. The
non-HCC group included both those with and without liver fibrosis, to reflect clinical HCC
screening scenarios. The high specificity of 0.95 (0.86–1.00) in separating HCC from those
with liver fibrosis offers important insights into the role of urinary VOCs as a screening
modality. The hypothesis that the hepatic CYP450 byproducts (VOCs) related to HCC
could be detected in different biological samples has been previously described. Two
studies have shown that VOCs can be detected in the headspace of incubated in vitro HCC
cells, supporting the use of VOC analysis for the assessment of hepatic enzyme function,
as well as for the prediction of HCC progression and metastasis [15,16]. Qin et al. [17]
utilized VOCs in the breath to identify HCC, independent of AFP levels or the disease’s
clinical stage. A recent study by Miller-Atkins et al. [18] showed that the use of 22 VOCs
in the breath could detect HCC with 0.73 sensitivity, compared with 0.53 for AFP in the
same cohort.
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Urine is a stable sample medium, and easier to collect for VOC analysis [19]. We
have previously reported that urinary VOC analysis using solid-phase microextraction
(SPME) was able to differentiate HCC and non-liver disease cases. The SPME AUC for
HCC with negative alpha fetoprotein (AFP) was 0.68, and it rose to 0.83 when combined
with raised AFP [20]. This was comparable to current findings reported here, where the
HCC AUC was 0.62 using GC-IMS, and 0.79 using GC-TOF-MS. The study reported here
also demonstrated the feasibility of urinary VOCs for differentiating between non-fibrotic,
fibrotic, and HCC cases, as demonstrated in Table 1 and Supplementary Tables S1 and S2.
Using GC-TOF-MS, we tentatively identified seven VOCs related to HCC, as shown
in Table 2. Though we did not perform verification and quantification of these chemicals,
we did undertake a search of these VOCs in relation to the development of HCC as per
the current literature. We found out that the most described VOC in HCC was 2-butanone.
In experimental models, exposure to 2-butanone led to hepatotoxicity by potentiating
dihydronicotinamide adenine dinucleotide phosphate (NADPH) cytochrome c reductase
activity, along with the concentration of cytochrome P450 enzymes. In addition, 2-butanone
exposure in these models, concomitantly with the known hepatocarcinogenic agent carbon
tetrachloride (CCI4), accelerated the formation of hepatotoxic metabolites and HCC. 2-
Butanone was also found to inhibit the activity of membrane-bound monoamine oxidase.
This is important because monoamine oxidase was found to suppress HCC metastasis
and progression by inhibiting the adrenergic system and its transactivation of epidermal
growth factor receptor (EGFR) signalling [21–30]. In human studies, 2-butanone was
found in the breath of HCC patients, and was found to have the best diagnostic value
among other organic compounds [17]. In NAFLD paediatric patients, 2-butanone appeared
at significantly higher levels in the faeces and was related to faecal Lachnospiraceae—a
family of anaerobic, spore-forming bacteria. Additionally, the study found that Oscillospirae
decrease relative to 2-butanone upregulation [31]. 2-Butanone was found to be elevated
in cirrhotic patients who underwent liver transplantation [32]. 2-Butanone levels in the
blood were found to be significantly discriminant in liver cancer patients, in comparison
to healthy individuals [33]. In breath studies looking into cirrhotic and non-cirrhotic liver
patients, serum bilirubin showed a positive correlation with 2-butanone. The 2-butanone
in the breath also distinguished different classes of liver cirrhosis, demonstrated by Child-
Turcotte-Pugh (CTP) scores of A, B and C [34,35].
We also tentatively identified 4-methyl-2,4-bis(p-hydroxyphenyl)pent-1-ene (MBP),
which is a derivative of bisphenol A (BPA), a major pollutant. In the liver, MBP metabolic
activation from BPA occurs via the cytochrome P450 system [36]. MBP can induce the
function of oestrogen in experimental models via activation of the oestrogen receptor
(ER) [37]. In patients with HCC, ERs are present and functional in around 50% of cases, but
their role in promoting carcinogenesis is still not fully clear [38]. The presence of urinary
MBP in HCC patients in this study suggests that MBP plays a role in HCC, perhaps via the
activation of ERs, but this requires further research.
Another VOC possibly found in this study related to HCC is 2-hexanone, which was
found to have a potentiating effect on the hepatotoxic agent chloroform, and subsequent
liver injury, in experimental animal models [39,40]. The mechanism for this was found to
be due to the induction of the CYP450 system [41–43]. Chronic inhalation of an isomer of
2-hexanone (methyl isobutyl ketone, MIBK) was found to cause hepatocellular adenomas
and HCC in mice [44–46]. This was shown to be in part due to the activation of the
pregnane X and constitutive androstane nuclear receptors; these receptors are responsible
for the regulation of CYP450 activity [44].
Benzene, 1-ethyl-2-methyl- has been identified as a blood biomarker of HCC in a
study using SPME-GC-MS [47]. Sulpiride is another chemical found in our study that is
closely related to many chronic liver diseases. In particular, sulpiride was found to be
related to biliary liver cirrhosis [48], NAFLD [49], and cholestatic hepatitis [50]. Though
it has not been identified as a biomarker for HCC, the presence of sulpiride indicates
that it may be a significant chemical for HCC. A study has suggested 3-butene-1,2-diol,
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1-(2-furanyl)- as an important VOC for lung cancer [51], but it has not been verified as an
HCC biomarker. Similarly, bicyclo[4.1.0]heptane, 3,7,7-trimethyl-, [1S-(1a,3β,6a)]-, found
in our study, has not been identified as a biomarker. Further investigation is needed to
confirm these chemicals in a larger cohort.
Our study was limited in not accounting for other factors that can be involved in the
production of VOCs, such as occupational environmental factors, diet, smoking, and drug
use. Another limitation was the small number of study participants. Nevertheless, this
study has answered the question of whether VOCs related to the function of CYP450 in HCC
can be detected in the urine. In particular, as discussed earlier, the tentative identification of
urinary VOCs in this study has been seen previously in various experimental and clinical
studies. The strong literature around 2-butanone encourages further study to identify the
exact biochemical pathways of this compound during HCC pathogenesis. However, we
did not validate these chemicals, nor did we quantify them; this effort will be undertaken
in a larger study. In addition, the data from the GC-IMS system were analysed using a
pattern recognition approach, and we did not attempt to identify chemical components.
Again, we propose to look further into this in the next study.
4. Materials and Methods
This pilot study was approved by the Coventry and Warwickshire and Northeast
Yorkshire NHS Ethics Committees (Ref 18717 and Ref 260179). The study conformed to
the ethical principles of the Declaration of Helsinki. Study participants were recruited
from University Hospital Coventry and the Warwickshire NHS Trust, UK. All participants
provided written informed consent. Five-millilitre urine samples were collected into
universal bottles from each study participant. These samples were then immediately frozen
at −80 ◦C within 1 to 2 h. The samples were then stored until further sample analysis at
the end of the recruitment process. We have previously tested the stability of urine samples
in storage, and all methods were in line with these findings [52,53].
4.1. Study Characteristics
There were a total of 58 participants. These included 20 HCC cases and 38 non-HCC
cases. The non-HCC cases were recruited from two sources in order to decrease bias: The
first source consisted of healthy individuals without liver disease. The second source
consisted of patients with different stages of NAFLD. The advantage here is that these
patients represent those at risk of becoming HCC cases in the future. The non-HCC cases
were then further divided into 31 non-fibrotic and 7 fibrotic/cirrhotic cases. The exclusion
criteria were pregnancy and age <18 years. All of the participants were recruited prior to
any anticancer treatment.
HCC diagnosis was made according to the current international guidelines, with
all inconclusive cases being confirmed by a liver biopsy. Liver fibrosis/cirrhosis was
confirmed by clinical examination and different radiological tests. In case of ambiguity
about the clinical diagnosis, a liver biopsy was performed so as to ascertain the cause of
the liver disease, and to look for the presence or absence of liver fibrosis/cirrhosis. We
further collected other clinical covariates of interest, including gender, age at the time of
urine sampling, history of absence or presence of diabetes, and the extent of HCC spread.
We also collected liver function tests at the time of urine sampling, including AFP, alanine
aminotransferase (ALT), alkaline phosphatase (ALP), albumin, and bilirubin. The study
participants’ characteristics are further detailed in Table 3.
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Table 3. Clinical and biochemical characteristics of the recruited study participants at the time of
obtaining their urine samples.
Covariate HCC Cases Non-HCC Cases
No. of Patients 20 38
Age: Mean (Range) 73 (53–84) 58.08 (29–89)
Gender: Female/Male 2/18 11/27










12 without Liver Disease
Histological/Radiological





AFP: Mean (Range), KU/L 1380.60 (1–9400) -
ALT: Mean (Range), U/L 44.60 (13–149) 50.74 (5–304)
ALP: Mean (Range), U/L 150.90 (83–326) 89.76 (53–279)
Albumin: Mean (Range), g/L 39 (24–44) 43.87 (28–50)
Bilirubin: Mean (Range),
µmol/L 24.30 (5–84) 7.97 (5–21)
Stage of the HCC:
Hepatic/Extra-Hepatic 13/7 -
Characteristics of the HCC and non-HCC groups. HCC diagnosis was made in line with international guidelines.
Liver disease was established using a combination of radiological scans, FibroScan, laboratory markers, and
histology. All covariates were collected at the time of urine collection. Abbreviations: AFP, alpha-fetoprotein; ALT,
alanine aminotransferase; ALP, alkaline phosphatase; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD,
non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis.
4.2. GC-IMS Methodology
Samples were shipped from University Hospital Coventry and from Warwickshire
in universal sample containers, on dry ice, to the School of Engineering, University of
Warwick, where they were stored at −20 ◦C until use. Prior to testing, the samples were
thawed overnight in a laboratory fridge at 4 ◦C. Once thawed, 5 mL of each urine sample
was aliquoted into 20 mL glass vials (Thames Restek, UK), and sealed with a PTFE crimp
cap (Thames Restek, UK). Samples were then analysed using a FlavourSpec GC-IMS
(G.A.S, Dortmund, Germany). The FlavourSpec was fitted with a CombiPAL autosampler,
allowing for high-throughput automatic analysis of the samples. The samples were loaded
into a cooled autosampler tray, keeping the samples at 4 ◦C. Each sample was heated to
40 ◦C and then agitated for 10 min prior to analysis. A 0.5 mL sample of the headspace
was then taken using the autosampler syringe and injected directly into the GC-IMS for
sampling. The GC–IMS settings were as follows: drift gas flow of 150 mL/m, and a carrier
gas flow rate of 20 mL/min. The drift gas used was 99.99% nitrogen. The IMS was heated
to 45 ◦C (T1), the GC to 40 ◦C (T2), the injector to 80 ◦C (T3), the T4 transfer line to 80 ◦C,
and the T5 transfer line to 45 ◦C. Sample analysis took 10 min. Once completed, the data
acquired were viewed using LAV software (G.A.S, Dortmund, Germany) and then exported
for further analysis. This method has been developed over several urinary VOC studies,
and is designed to maximize information content and chemical separation [12,54]. This
includes the volume of urine, agitation period, and temperature. For quality control, blank
samples were added at the beginning and end of each run, with the instrument having
regular calibration checks run. Furthermore, the information content of each sample was
checked, which included a visual inspection of each sample file.
4.3. GC-TOF-MS Methodology
A subset of samples was also analysed using GC-TOF-MS (Markes International, UK),
with a UNITY-xr thermal desorber and ULTRA-xr autosampler (Markes International, UK).
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Urine samples for GC-TOF-MS were aliquoted as outlined, with about 5 mL of each sample
in a 20 mL vial, which was sealed with a crimp camp. The headspace of each urine sample
was then adsorbed onto a Markes bio-monitoring tube (C2-AAXX-5149). The septum of the
vial was pierced, and the sorbent tube pushed through into the headspace in the vial. The
samples were then heated to 40 ◦C for 20 min, before a pump was attached to the sorbent
tube and the sample was pulled through onto the sorbent bed of the tube for 20 min whilst
still being heated to 40 ◦C. Once complete, the tube was removed from the vial and placed
into the Markes ULTRA-xr autosampler. The ULTRA-xr autosampler was set to run with
a standby split of 150 ◦C, and a GC temperature ramp of 20 ◦C per minute, heating from
40 ◦C to 280 ◦C with a GC run time of 25 min. The samples were each pre-purged for
1 min, following which the sorbent tube was desorbed onto the trap for 10 min at 250 ◦C.
Once complete, the trap was purged for a further minute and then cooled to 30 ◦C, before
being heated to 300 ◦C for 3 min. Post-analysis, a dynamic baseline correction (DBS) was
applied using the native TOF-DS software, and the chromatogram was integrated and
deconvoluted with the following settings: global height reject of 10,000, global width reject
of 0.01, baseline threshold of 3, and global area reject of 10,000. The peaks identified were
then compared with the NIST list, with a match (forward and reverse) factor of 450, to
identify the compounds present. As with GC–IMS, this method has been used in a number
of VOC studies, including those associated with cancer, and has been previously reported
on [52].
4.4. Statistical Analysis
The analysis of the data was undertaken using our previously reported data analysis
pipeline for GC-IMS and GC-TOF-MS data, using “R” (version 3.6.3) [12–14]. In brief, for
GC–IMS data, we applied a two-stage pre-processing step. This was undertaken because
the dataset has high dimensionality (typically 11 million data points), but low chemical
information. The first step was to crop the central section of the output data, where all of
the chemical information is located. This was followed by the application of a threshold,
below which all values were given a value of zero. This was undertaken to remove the
background, leaving just the chemical information. The crop parameters were manually
selected, and the same values were applied to all of the data. The threshold was defined
by the value of the background noise. The data were then processed using a 10-fold
cross validation. Here, the data were split into a 90% training set and a 10% test set.
Within each fold, a Wilcoxon rank sum test was undertaken, and the 100 features with the
lowest p-value were extracted. Classification models were constructed using two classifiers
(eXtreme Gradient Boosting (XGBoost), and logistic regression). This process was repeated
until all of the samples had been in the test group. The results were then collated, and
from the resultant probabilities, statistical parameters, including sensitivity and specificity,
were calculated.
For GC-TOF-MS, a similar process was undertaken. However, in this case, we used
chemical identification to create features and, due to the much lower dimensionality, these
were used directly by the classifier with no additional feature reduction. A further step
used here was to undertake the statistical analysis of each chemical. A non-parametric t-test
was undertaken in order to calculate the p-value of each chemical, comparing the samples
in the two groups. Those chemicals found to have a p-value of <0.05 were considered
statistically important.
5. Conclusions
Urinary VOCs can identify HCC cases non-invasively. The putative VOCs are likely
related to CYP450 function in HCC. Our study further highlights how urine can provide a
good medium for the investigation of metabolic function in HCC for further work on the
cellular level.
Supplementary Materials: The following are available online: Table S1 compares HCC with non-
HCC cases using GC–IMS analysis, providing AUC, sensitivity, specificity, thresholds, negative
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predictive value, and positive predictive value. Table S2 compares HCC with non-HCC cases using
GC–TOF-MS analysis, providing AUC, sensitivity, specificity, thresholds, negative predictive value,
and positive predictive value. Table S3 shows the identified chemicals for Fibrosis vs Non-Fibrosis
that were statistically relevant using GC-TOF-MS. Figure S1 provides ROCs for HCC and Fibrosis
samples, HCC and Non-Fibrosis and Fibrosis and Non-Fibrosis using GC-TOF-MS.
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